COA on every batch · Same-day dispatch by 2PM EST · For in-vitro research use only
Menu
Research-grade peptides
Every batch verified twice — HPLC and mass spectrometry — with a public Certificate of Analysis. Order by 2PM EST and it ships today.
Best Sellers
Shop all
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with a molecular formula of C225H348N48O68 and molecular weight of 4813.5 g/mol (CAS: 2023788-19-2). It is engineered as a 39-amino acid synthetic peptide based on the native GIP sequence, modified with a C-20 fatty diacid moiety that enables once-weekly dosing through prolonged albumin binding. Research demonstrates that tirzepatide uniquely activates both GIP and GLP-1 receptors, producing complementary metabolic effects. Studies show GIP receptor activation enhances insulin sensitivity in adipose tissue and promotes lipid metabolism, while simultaneous GLP-1 receptor engagement stimulates glucose-dependent insulin secretion and suppresses glucagon release. This dual mechanism has shown superior glycemic and weight outcomes compared to selective GLP-1 receptor agonists in clinical trials. Preclinical investigations have revealed tirzepatide’s effects on energy expenditure, hepatic lipid metabolism, and inflammatory pathways. Research in animal models demonstrates reduced hepatic steatosis, improved mitochondrial function in adipose tissue, and modulation of appetite-regulating neuropeptides in the hypothalamus. Studies also document improvements in cardiovascular risk markers including triglycerides, LDL cholesterol, and blood pressure. Each vial contains 30mg of lyophilized tirzepatide at greater than 99.9% purity, independently verified by HPLC and mass spectrometry. Supplied as a sterile, white to off-white lyophilized powder for reconstitution with bacteriostatic water.
$217.99· ships same-day
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with a molecular formula of C225H348N48O68 and molecular weight of 4813.5 g/mol (CAS: 2023788-19-2). It is engineered as a 39-amino acid synthetic peptide based on the native GIP sequence, modified with a C-20 fatty diacid moiety that enables once-weekly dosing through prolonged albumin binding. Research demonstrates that tirzepatide uniquely activates both GIP and GLP-1 receptors, producing complementary metabolic effects. Studies show GIP receptor activation enhances insulin sensitivity in adipose tissue and promotes lipid metabolism, while simultaneous GLP-1 receptor engagement stimulates glucose-dependent insulin secretion and suppresses glucagon release. This dual mechanism has shown superior glycemic and weight outcomes compared to selective GLP-1 receptor agonists in clinical trials. Preclinical investigations have revealed tirzepatide’s effects on energy expenditure, hepatic lipid metabolism, and inflammatory pathways. Research in animal models demonstrates reduced hepatic steatosis, improved mitochondrial function in adipose tissue, and modulation of appetite-regulating neuropeptides in the hypothalamus. Studies also document improvements in cardiovascular risk markers including triglycerides, LDL cholesterol, and blood pressure. Each vial contains 30mg of lyophilized tirzepatide at greater than 99.9% purity, independently verified by HPLC and mass spectrometry. Supplied as a sterile, white to off-white lyophilized powder for reconstitution with bacteriostatic water.
$217.99· ships same-day
Strictly for in-vitro research. Not for human or animal consumption.
Most Loved
The peptides researchers reorder most — purity-verified and ready to ship the same day.
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with a molecular formula of C225H348N48O68 and molecular weight of 4813.5 g/mol (CAS: 2023788-19-2). It is engineered as a 39-amino acid synthetic peptide based on the native GIP sequence, modified with a C-20 fatty diacid moiety that enables once-weekly dosing through prolonged albumin binding. Research demonstrates that tirzepatide uniquely activates both GIP and GLP-1 receptors, producing complementary metabolic effects. Studies show GIP receptor activation enhances insulin sensitivity in adipose tissue and promotes lipid metabolism, while simultaneous GLP-1 receptor engagement stimulates glucose-dependent insulin secretion and suppresses glucagon release. This dual mechanism has shown superior glycemic and weight outcomes compared to selective GLP-1 receptor agonists in clinical trials. Preclinical investigations have revealed tirzepatide’s effects on energy expenditure, hepatic lipid metabolism, and inflammatory pathways. Research in animal models demonstrates reduced hepatic steatosis, improved mitochondrial function in adipose tissue, and modulation of appetite-regulating neuropeptides in the hypothalamus. Studies also document improvements in cardiovascular risk markers including triglycerides, LDL cholesterol, and blood pressure. Each vial contains 30mg of lyophilized tirzepatide at greater than 99.9% purity, independently verified by HPLC and mass spectrometry. Supplied as a sterile, white to off-white lyophilized powder for reconstitution with bacteriostatic water.
$217.99· ships same-day
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with a molecular formula of C225H348N48O68 and molecular weight of 4813.5 g/mol (CAS: 2023788-19-2). It is engineered as a 39-amino acid synthetic peptide based on the native GIP sequence, modified with a C-20 fatty diacid moiety that enables once-weekly dosing through prolonged albumin binding. Research demonstrates that tirzepatide uniquely activates both GIP and GLP-1 receptors, producing complementary metabolic effects. Studies show GIP receptor activation enhances insulin sensitivity in adipose tissue and promotes lipid metabolism, while simultaneous GLP-1 receptor engagement stimulates glucose-dependent insulin secretion and suppresses glucagon release. This dual mechanism has shown superior glycemic and weight outcomes compared to selective GLP-1 receptor agonists in clinical trials. Preclinical investigations have revealed tirzepatide’s effects on energy expenditure, hepatic lipid metabolism, and inflammatory pathways. Research in animal models demonstrates reduced hepatic steatosis, improved mitochondrial function in adipose tissue, and modulation of appetite-regulating neuropeptides in the hypothalamus. Studies also document improvements in cardiovascular risk markers including triglycerides, LDL cholesterol, and blood pressure. Each vial contains 30mg of lyophilized tirzepatide at greater than 99.9% purity, independently verified by HPLC and mass spectrometry. Supplied as a sterile, white to off-white lyophilized powder for reconstitution with bacteriostatic water.
$217.99· ships same-day
Our Standard
Reliable research needs uncompromised materials. Every synthesis is verified by an independent third-party laboratory, and we publish a public, up-to-date Certificate of Analysis for every batch — no exceptions, no fine print.
99%+
HPLC purity, every batch
2×
Verified — HPLC and mass spec
100%
COAs published publicly
2PM
Order by 2PM EST, ships today
